GlassScriptPhysician profile
David S Caras
NPI 1275500308
$9,748.81
in general payments reported to CMS, 2019-2025
29 companies · $1,321 in 2025
The $1,321 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,029 · 2021: $1,127 · 2022: $1,725 · 2023: $1,814 · 2024: $1,675 · 2025: $1,321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,780 · Education: $29.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,780.41 |
| Education | $29.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,871.46 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,159.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $983.54 | 2019-2025 | Brilinta, Farxiga, Lokelma |
| Pfizer INC. | $945.91 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $647.02 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $640.97 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $635.24 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $519.20 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $399.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $378.62 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $331.96 | 2021-2025 | |
| Boston Scientific Corporation | $268.95 | 2019-2023 | |
| Heartflow, INC. | $185.17 | 2022-2023 | Ffrct |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.88 | 2024-2025 | Lifevest |
| Cvrx, INC. | $95.55 | 2022-2023 | Barostim Neo System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $86.33 | 2023-2025 | Opsumit, Uptravi |
| Abiomed | $84.75 | 2025 | |
| W. L. Gore & Associates, INC. | $81.37 | 2020-2021 | |
| Amarin Pharma, INC. | $77.20 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $51.74 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $49.43 | 2019-2024 | |
| Lundbeck LLC | $33.01 | 2020 | |
| Arbor Pharmaceuticals, INC. | $28.52 | 2019-2020 | |
| Edwards Lifesciences Corporation | $20.69 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.89 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2020 | |
| Irhythm Technologies, INC. | $15.64 | 2022 | |
| Cmp Pharma, INC. | $15.27 | 2020 | |
| Gilead Sciences, INC. | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Caras listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.